GlobeNewsWire
17 Mar 2026, 20:09 UTC · 30w ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREO
Impact · against what's priced in
The article confirms the catastrophic failure of Mereo BioPharma's Phase 3 trials and the subsequent legal fallout, which have already triggered a massive collapse in share price. For Mereo and its partner Ultragenyx, the news is redundant as the market has already reacted to the failed endpoints; for Abeona and Azenta, the news introduces new, though secondary, legal risk.
- MREO−0.60
No priced-in read yet





